Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™
November 26 2023 - 11:00AM
Business Wire
- The Company announces a new identity for its iBiopsy® AI/ML
tech-based suite of software as medical devices (SaMD), and
business unit.
- iBiopsy® becomes eyonis™.
- eyonis™ brand visual identity is unveiled today at the
Radiological Society of North America (RSNA) 2023 Annual Meeting,
taking place in Chicago, IL, USA, Nov. 26-30.
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231126347438/en/
Median Technologies (Paris:ALMDT) today unveils a new identity,
including a new name, logo, tagline for its iBiopsy® AI/ML
tech-based suite of software as medical devices (SaMD) and business
unit, as part of an extensive rebranding initiative.
Starting today, the Company has officially rebranded iBiopsy® to
the new name of eyonis™. This rebranding marks a significant
milestone in Median’s corporate trajectory and underscores the
Company’s unwavering dedication to delivering cutting-edge Software
as Medical Devices (SaMD) to the radiology market. The new brand
identity fully aligns with Median’s vision for the future, and the
path the Company is charting.
Median’s new brand name eyonis™ brings “Eye” at the forefront,
to create a connection to visual imaging then combined with “Onis”
which takes it to power, and efficacy. This concept resonates with
Median’s mission, and therefore, the new eyonis™ brand tagline is
"Catching the Unseen”, that perfectly encapsulates Median’s
commitment to harnessing the power of medical images combined with
the strength of Artificial Intelligence to bring previously unseen
insights to light with efficacy in order to enable better and
earlier diagnosis of patients.
"As a reflection of our commitment to bringing the best of AI/ML
tech-based methodologies to software as medical devices to help
fight cancers, we embark on a transformative journey from iBiopsy®
to eyonis™, a new brand name with an etymology linked to vision,
power, and efficacy. As we step into these new horizons, we carry
with us the rich heritage and brand equity of iBiopsy®, and we
stand poised to capitalize on our reputation with eyonis™ as a
renewed vision, to build on the foundation of excellence that has
defined us and will redefine benchmarks of success in the early
diagnosis of cancers," Thomas Bonnefont, COO and CCO of eyonis™
said.
eyonis™ brand visual identity is unveiled today at the opening
of the Radiological Society of North America (RSNA) 2023 Annual
Meeting, taking place in Chicago, IL, USA. Median’s teams will be
at booth #4465, Level 3 South Hall (AI showcase) to present the
latest development of eyonis™, Median’s AI/ML tech-based suite of
Software as Medical Devices. eyonis™ will be the commercial name of
Median’s SaMD portfolio in the US and Europe once the Company
receives the 510K clearance from the FDA and the CE marking in
Europe.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and eyonis™, our
AI/ML tech-based suite of software as medical devices (SaMD), help
biopharmaceutical companies and clinicians to bring new treatments
and diagnose patients earlier and more accurately. This is how we
are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231126347438/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Apr 2024 to May 2024
Median Technologies (EU:ALMDT)
Historical Stock Chart
From May 2023 to May 2024